Skip to main content
. 2019 Nov 18;12:9827–9848. doi: 10.2147/OTT.S227541

Table 3.

Clinico-Pathological Value Of MIR22HG Expression In HCC From mRNA-Seq Data

Clinico-Pathological Feature N MIR22HG Relevant Expression
M ± SD t P
Tissue Cancer 374 2.879 ± 0.948 −8.63 <0.001
Normal 225 3.678 ± 1.179
Gender MALE 250 2.860 ± 0.954 −0.872 0.384
FEMALE 121 2.951 ± 0.927
Age >60 193 2.957 ± 0.904 1.514 0.131
≤60 177 2.808 ± 0.981
Stage III-IV 90 2.733 ± 1.035 1.486 0.138
I-II 257 2.904 ± 0.905
M stage M1 4 2.009 ± 0.619 1.648 0.101
M0 266 2.814 ± 0.973
N stage N1 4 3.330 ± 1.497 −1.071 0.285
N0 252 2.808 ± 0.960
T stage T3-4 93 2.746 ± 0.993 1.647 0.100
T0-2 275 2.932 ± 0.926
Grade G3-4 134 2.734 ± 0.991 2.365 0.019
G1-2 232 2.976 ± 0.912

Notes: Unpaired sample t test was performed to evaluate the clinico-pathological parameters of HCC. P<0.05 was considered statistically significant.

Abbreviations: N, number; M, mean; SD, standard deviation.